The inspection closed with the facility receiving an inspection classification of NAI
The inspection closed with zero observations
The company will submit its comprehensive response on these observations to the US FDA
Total investments could reach €70 million, of which approximately 15% in R&D and 85% in capex, that would be deployed from 2026
The additional $50 million will go towards venture capital firms that specialize in near- and long-term healthcare solutions for patients in low- and middle-income countries
Allianz is ISO 9001:2015 certified and INVIMA certified for storage, sampling, dispensation, and distribution of APIs to the Colombian market
Collaboration will enable rapid advancement of a joint preclinical proof of concept program for type 1 diabetes
Venkat Nageswar Chalasani has been appointed as an Independent Director of Apitoria Pharma with effect from April 4, 2023
Subscribe To Our Newsletter & Stay Updated